凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
华兰生物(002007)公告正文

华兰生物:2015年第一季度报告全文

公告日期 2015-04-23
股票简称:华兰生物 股票代码:002007
                华兰生物工程股份有限公司 2015 年第一季度报告全文华兰生物工程股份有限公司
    2015 年第一季度报告
      2015 年 04 月
                                                       华兰生物工程股份有限公司 2015 年第一季度报告全文
                                    第一节 重要提示
       公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
       除下列董事外,其他董事亲自出席了审议本次季报的董事会会议
    未亲自出席董事姓名      未亲自出席董事职务      未亲自出席会议原因              被委托人姓名
    章金刚                  独立董事                工作原因                  苏志国
    安颖                    董事                    工作原因                  安康
       公司负责人安康、主管会计工作负责人谢军民及会计机构负责人(会计主管人员)王建体声明:保证季度报告中财务报表的真实、准确、完整。
                                                                 华兰生物工程股份有限公司 2015 年第一季度报告全文
                              第二节 主要财务数据及股东变化一、主要会计数据和财务指标公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据□ 是 √ 否
                                            本报告期                   上年同期             本报告期比上年同期增减
    营业收入(元)                                  298,070,108.06             278,440,387.76                      7.05%
    归属于上市公司股东的净利润(元)                149,576,847.82             174,398,390.97                     -14.23%归属于上市公司股东的扣除非经常性损
                                                119,315,905.97             132,414,582.71                      -9.89%益的净利润(元)
    经营活动产生的现金流量净额(元)                 36,131,796.25             103,989,566.97                     -65.25%
    基本每股收益(元/股)                                   0.2573                    0.3002                      -14.29%
    稀释每股收益(元/股)                                   0.2573                    0.3002                      -14.29%
    加权平均净资产收益率                                     4.30%                     5.51%                       -1.21%
                                                                                            本报告期末比上年度末增
                                           本报告期末                  上年度末
                                                                                                         减
    总资产(元)                                  3,934,186,081.75           3,769,637,163.08                      4.37%
    归属于上市公司股东的净资产(元)              3,555,766,924.98           3,402,382,635.49                      4.51%非经常性损益项目和金额√ 适用 □ 不适用
                                                                                                              单位:元
                           项目                            年初至报告期期末金额                   说明
    非流动资产处置损益(包括已计提资产减值准备的冲销部分)                   -108,548.24计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                        3,200,000.00一标准定额或定量享受的政府补助除外)
    除上述各项之外的其他营业外收入和支出                                     -595,611.19
    其他符合非经常性损益定义的损益项目                                     33,079,957.89
    减:所得税影响额                                                        5,336,474.77
       少数股东权益影响额(税后)                                         -21,618.16
    合计                                                                   30,260,941.85                --对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应说明原因□ 适用 √ 不适用
                                                              华兰生物工程股份有限公司 2015 年第一季度报告全文公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益项目界定为经常性损益的项目的情形。二、报告期末股东总数及前十名股东持股情况表1、报告期末普通股股东总数及前十名普通股股东持股情况表
                                                                                                            单位:股
    报告期末普通股股东总数                                                                                          34,835
                                          前 10 名普通股股东持股情况
                                                    持股比                 持有有限售条         质押或冻结情况
               股东名称               股东性质               持股数量
                                                      例                   件的股份数量    股份状态        数量
    江西永喆实业有限公司               境内非国有法人   17.67%   102,723,822               0
    重庆市晟康生物科技开发有限公司     境内非国有法人   15.13%    87,961,115               0
    香港科康有限公司                   境内非国有法人   13.23%    76,889,088               0
    新乡市世辰生物技术有限公司         境内非国有法人    3.66%    21,247,640               0中国工商银行-汇添富均衡增长股票
                                   境内非国有法人    1.03%     6,000,000               0型证券投资基金中国工商银行股份有限公司-汇添富
                                   境内非国有法人    0.96%     5,592,259               0医药保健股票型证券投资基金新华人寿保险股份有限公司-分红-
                                   境内非国有法人    0.91%     5,316,356               0个人分红-018L-FH002 深
    全国社保基金一一零组合             境内非国有法人    0.82%     4,766,454               0中国人民财产保险股份有限公司-传
                                   境内非国有法人    0.67%     3,905,749               0统-收益组合中国人寿保险股份有限公司-传统-
                                   境内非国有法人    0.60%     3,500,000               0普通保险产品-005L-CT001 深
                                     前 10 名无限售条件普通股股东持股情况
                                                                                              股份种类
               股东名称                  持有无限售条件普通股股份数量
                                                                                   股份种类              数量
    江西永喆实业有限公司                                               102,723,822 人民币普通股              102,723,822
    重庆市晟康生物科技开发有限公司                                      87,961,115 人民币普通股               87,961,115
    香港科康有限公司                                                    76,889,088 人民币普通股               76,889,088
    新乡市世辰生物技术有限公司                                          21,247,640 人民币普通股               21,247,640中国工商银行-汇添富均衡增长股票
                                                                       6,000,000 人民币普通股              6,000,000型证券投资基金中国工商银行股份有限公司-汇添富
                                                                       5,592,259 人民币普通股              5,592,259医药保健股票型证券投资基金
                                                             华兰生物工程股份有限公司 2015 年第一季度报告全文新华人寿保险股份有限公司-分红-
                                                                    5,316,356 人民币普通股         5,316,356个人分红-018L-FH002 深
    全国社保基金一一零组合                                              4,766,454 人民币普通股         4,766,454中国人民财产保险股份有限公司-传
                                                                    3,905,749 人民币普通股         3,905,749统-收益组合中国人寿保险股份有限公司-传统-
                                                                    3,500,000 人民币普通股         3,500,000普通保险产品-005L-CT001 深
                                   上述第一、二、三股东存在关联关系,属于一致行动人。中国工商银行-汇添富均上述股东关联关系或一致行动的说明 衡增长股票型证券投资基金和中国工商银行-汇添富医药保健股票型证券投资基金
                                   同为汇添富基金管理有限公司旗下基金 。公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内是否进行约定购回交易□ 是 √ 否公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内未进行约定购回交易。2、报告期末优先股股东总数及前十名优先股股东持股情况表□ 适用 √ 不适用
                                                               华兰生物工程股份有限公司 2015 年第一季度报告全文
                                         第三节 重要事项一、报告期主要会计报表项目、财务指标发生变动的情况及原因√ 适用 □ 不适用1、应收票据期末余额较期初余额增加36.80%,主要原因是公司销售货物部分货款以银行承兑汇票结算所致;2、生产性生物资产期末余额较期初余额减少45.29%,主要原因是本公司之孙公司新乡市太行禽业有限公司处理成鸡所致;3、其他非流动资产期末余额较期初余额增加133.53%,主要原因是本期预付工程款、设备款增加所致;4、预收账款期末余额较期初余额增加138.70%,主要原因是预收货款尚未到结算期所致;5、营业税金及附加本报告期较上年同期减少34.21%,主要原因是公司增值税税率由上年同期的6%调整为3%,增值税减少,相应附征减少所致;6、投资收益本报告期较上年同期增加128.43%,主要原因是本报告期理财收益增加所致;7、营业外收入本报告期较上年同期减少90.82%,主要原因是上年同期收到政府补助,而本报告期收到政府补助减少所致;8、经营活动产生的现金流量净额本报告期较上年同期减少65.25%,主要原因一是上年同期收到政府补助,而本报告期收到政府补助减少;二是新建浆站开采及采浆量增加相应购买商品所支付的现金增加所致;9、投资活动产生的现金流量净额本报告期较上年同期增加152.40%,主要原因是本报告期部分理财产品本金及收益收回所致;10、筹资活动产生的现金流量净额本报告期较上年同期减少9124.50万元,主要原因是上年同期本公司之子公司华兰生物工程重庆有限公司偿还银行借款及利息,而本报告期无此项业务所致。二、重要事项进展情况及其影响和解决方案的分析说明□ 适用 √ 不适用三、公司或持股 5%以上股东在报告期内发生或以前期间发生但持续到报告期内的承诺事项√ 适用 □ 不适用
        承诺事由           承诺方                  承诺内容                   承诺时间     承诺期限    履行情况
    股改承诺                 不适用     不适用                                                不适用      不适用收购报告书或权益变动报
                         不适用     不适用                                                不适用      不适用告书中所作承诺
    资产重组时所作承诺       不适用     不适用                                                不适用      不适用
                                    为避免同业竞争引起的损害本公司及其他
                                    股东利益,本公司实际控制人安康先生承
                                    诺:"作为本公司实际控制人期间,不在与
    首次公开发行或再融资时                                                       2004 年 06               正在严格履
                         实际控制人 本公司构成同业竞争的其他公司任职,在其                长期有效
    所作承诺                                                                     月 25 日                 行中
                                    经营业务中将不会利用其在本公司及本公
                                    司股东中的地位从事任何有损本公司及其
                                    他股东利益的行为。"
    其他对公司中小股东所作 董事会       公司未来三年(2012-2014 年)的具体股东 2012 年 08     2012-2014   正在严格履
                                                           华兰生物工程股份有限公司 2015 年第一季度报告全文
    承诺                            回报规划:1、公司可以采取现金、股票、 月 29 日          年度        行中
                                现金与股票相结合或者法律、法规允许的其
                                他方式分配利润。2、根据《公司法》等有
                                关法律法规及《公司章程》的规定,在公司
                                盈利且现金能够满足公司持续经营和长期
                                发展、符合现金分红条件的前提下,
                                2012-2014 年每年以现金方式分配的利润应
                                不低于当年实现的可分配利润的 10%,且连
                                续三年内以现金方式累计分配的利润不少
                                于该三年实现的年均可分配利润的 30%。
                                3、未来三年(2012-2014 年)公司原则上每
                                年度进行一次现金分红,公司董事会可以根
                                据公司盈利情况及资金需求状况提议公司
                                进行中期现金分红。 4、未来三年
                                (2012-2014)公司可以根据累计可供分配
                                利润、公积金及现金流状况,在保证最低现
                                金分红比例和公司股本规模合理的前提下,
                                为保持股本扩张与业绩增长相适应,公司可
                                以采取股票股利方式进行利润分配,具体分
                                红比例由公司董事会审议通过后,并提交股
                                东大会审议决定。
                                实际控制人安康先生承诺:自限制性股票授
                                                                           2013 年 05   至 2016 年 8 正在严格履
                   实际控制人 予日起三十六个月内不转让获授限制性股
                                                                           月 27 日     月 27 日    行中
                                票。
                                (1)激励对象所获授的限制性股票及相应
                                的股票股利锁定期满在二级市场上出售或
                                以其他方式转让时,应当符合《公司法》、
                                《证券法》、《上市规则》等法律法规以及华
                                兰生物公司治理文件的相关规定。(2)公司
                                董事、高管所获授的限制性股票及股票股利
                                在解锁期内出售应遵循《公司法》、《证券
                   除实际控制
                                法》、《上市规则》的限售规定。即:作为公 2013 年 05     至 2016 年 8 正在严格履
                   人外的其他
                                司董事、高管的激励对象每年转让其持有的 月 27 日         月 27 日    行中
                   激励对象
                                华兰生物股票不得超过其所持有的公司股
                                票总数的百分之二十五,在离职后六个月内
                                不得转让其所有的公司股份。在申报离任六
                                个月后的十二月内通过证券交易所挂牌交
                                易出售本公司股票数量占其所持有本公司
                                股票总数(包括有限售条件和无限售条件的
                                股份)的比例不得超过 50%。
    承诺是否及时履行   是
                                                                华兰生物工程股份有限公司 2015 年第一季度报告全文四、对 2015 年 1-6 月经营业绩的预计2015 年 1-6 月预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形
    2015 年 1-6 月归属于上市公司股东的净利润变动幅度                     0.00%    至                          10.00%2015 年 1-6 月归属于上市公司股东的净利润变动区间(万
                                                                  28,560.12   至                        31,416.13元)
    2014 年 1-6 月归属于上市公司股东的净利润(万元)                                                        28,560.12
                                                       公司预计 2015 年 1-6 月份归属于上市公司股东的净利润同比变业绩变动的原因说明
                                                       动 0%-10%,主要原因是公司血液制品销售收入增加。五、证券投资情况□ 适用 √ 不适用公司报告期不存在证券投资。六、持有其他上市公司股权情况的说明□ 适用 √ 不适用公司报告期未持有其他上市公司股权。
                                                         华兰生物工程股份有限公司 2015 年第一季度报告全文
                                     第四节 财务报表一、财务报表1、合并资产负债表编制单位:华兰生物工程股份有限公司
                                       2015 年 03 月 31 日
                                                                                                    单位:元
                 项目                    期末余额                                期初余额流动资产:
    货币资金                                         860,361,873.56                          672,055,314.21
    结算备付金
    拆出资金
    以公允价值计量且其变动计入当期损益的金融资产
    衍生金融资产
    应收票据                                          48,982,891.68                           35,805,954.76
    应收账款                                         161,990,590.77                          152,617,010.56
    预付款项                                          24,288,857.36                           16,931,128.31
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息
    应收股利
    其他应收款                                         6,544,180.45                            4,503,486.90
    买入返售金融资产
    存货                                             539,884,066.97                          474,502,751.68
    划分为持有待售的资产
    一年内到期的非流动资产                                                                   100,000,000.00
    其他流动资产                                     995,000,000.00                         1,050,000,000.00
    流动资产合计                                        2,637,052,460.79                        2,506,415,646.42非流动资产:
    发放贷款及垫款
                                        华兰生物工程股份有限公司 2015 年第一季度报告全文
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                     34,889,750.97                         37,157,543.24
    投资性房地产
    固定资产                        754,123,893.82                        774,320,713.72
    在建工程                        203,430,305.93                        183,609,152.07
    工程物资
    固定资产清理
    生产性生物资产                    1,009,683.56                          1,845,444.24
    油气资产
    无形资产                        204,846,743.99                        206,432,408.86
    开发支出
    商誉
    长期待摊费用                       1,711,099.00                         2,057,767.00
    递延所得税资产                   25,801,915.97                         27,258,755.86
    其他非流动资产                   71,320,227.72                         30,539,731.67
    非流动资产合计                     1,297,133,620.96                     1,263,221,516.66
    资产总计                           3,934,186,081.75                     3,769,637,163.08流动负债:
    短期借款
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    以公允价值计量且其变动计入当期损益的金融负债
    衍生金融负债
    应付票据
    应付账款                         52,453,530.60                         43,258,948.05
    预收款项                         11,792,198.02                          4,940,197.65
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                        605,862.19                           522,023.40
    应交税费                         28,055,479.41                         27,119,860.56
                                华兰生物工程股份有限公司 2015 年第一季度报告全文
    应付利息
    应付股利
    其他应付款                55,991,168.44                        57,855,948.53
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    划分为持有待售的负债
    一年内到期的非流动负债
    其他流动负债
    流动负债合计                 148,898,238.66                       133,696,978.19非流动负债:
    长期借款
    应付债券
      其中:优先股
               永续债
    长期应付款
    长期应付职工薪酬
    专项应付款
    预计负债
    递延收益
    递延所得税负债
    其他非流动负债非流动负债合计
    负债合计                     148,898,238.66                       133,696,978.19所有者权益:
    股本                     581,304,800.00                       581,304,800.00
    其他权益工具
      其中:优先股
               永续债
    资本公积                 370,917,093.70                       367,109,652.03
    减:库存股
    其他综合收益
    专项储备
                                                             华兰生物工程股份有限公司 2015 年第一季度报告全文
    盈余公积                                             288,493,594.04                          288,493,594.04
    一般风险准备
    未分配利润                                          2,315,051,437.24                        2,165,474,589.42
    归属于母公司所有者权益合计                              3,555,766,924.98                        3,402,382,635.49
    少数股东权益                                         229,520,918.11                          233,557,549.40
    所有者权益合计                                          3,785,287,843.09                        3,635,940,184.89
    负债和所有者权益总计                                    3,934,186,081.75                        3,769,637,163.08
    法定代表人:安康                   主管会计工作负责人:谢军民                        会计机构负责人:王建体2、母公司资产负债表
                                                                                                        单位:元
                 项目                        期末余额                                期初余额流动资产:
    货币资金                                             569,661,242.16                          298,094,612.90
    以公允价值计量且其变动计入当期损益的金融资产
    衍生金融资产
    应收票据                                              47,982,891.68                           28,607,225.00
    应收账款                                              47,609,234.96                           35,463,504.06
    预付款项                                              62,233,040.55                           35,507,849.42
    应收利息
    应收股利
    其他应收款                                            45,958,128.29                          114,232,320.41
    存货                                                 242,170,487.40                          244,288,764.53
    划分为持有待售的资产
    一年内到期的非流动资产                                                                       100,000,000.00
    其他流动资产                                         715,000,000.00                          760,000,000.00
    流动资产合计                                            1,730,615,025.04                        1,616,194,276.32非流动资产:
    可供出售金融资产
    持有至到期投资
    长期应收款                                             5,379,060.00                            5,379,060.00
    长期股权投资                                         637,756,448.08                          640,024,240.35
    投资性房地产
                                        华兰生物工程股份有限公司 2015 年第一季度报告全文
    固定资产                        211,104,257.35                        219,145,680.11
    在建工程                        167,878,835.93                        151,029,152.07
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                        121,080,525.59                        121,957,778.72
    开发支出
    商誉
    长期待摊费用                       1,711,099.00                         2,057,767.00
    递延所得税资产                    3,917,259.22                          3,917,259.22
    其他非流动资产                   49,791,746.32                         24,985,470.77
    非流动资产合计                     1,198,619,231.49                     1,168,496,408.24
    资产总计                           2,929,234,256.53                     2,784,690,684.56流动负债:
    短期借款
    以公允价值计量且其变动计入当期损益的金融负债
    衍生金融负债
    应付票据
    应付账款                         31,687,446.31                         30,940,339.59
    预收款项                         12,761,248.00                           759,160.00
    应付职工薪酬                        279,717.26                           156,336.00
    应交税费                         17,931,824.47                         15,524,585.63
    应付利息
    应付股利
    其他应付款                        4,222,784.86                          1,424,940.23
    划分为持有待售的负债
    一年内到期的非流动负债
    其他流动负债
    流动负债合计                         66,883,020.90                         48,805,361.45非流动负债:
    长期借款
    应付债券
                                    华兰生物工程股份有限公司 2015 年第一季度报告全文
      其中:优先股
               永续债
    长期应付款
    长期应付职工薪酬
    专项应付款
    预计负债
    递延收益
    递延所得税负债
    其他非流动负债非流动负债合计
    负债合计                          66,883,020.90                          48,805,361.45所有者权益:
    股本                         581,304,800.00                         581,304,800.00
    其他权益工具
      其中:优先股
               永续债
    资本公积                     379,664,891.21                         375,857,449.54
    减:库存股
    其他综合收益
    专项储备
    盈余公积                     288,493,594.04                         288,493,594.04
    未分配利润                 1,612,887,950.38                     1,490,229,479.53
    所有者权益合计                 2,862,351,235.63                     2,735,885,323.11
    负债和所有者权益总计           2,929,234,256.53                     2,784,690,684.563、合并利润表
                                                                              单位:元
                        项目   本期发生额                  上期发生额
    一、营业总收入                   298,070,108.06                         278,440,387.76
    其中:营业收入               298,070,108.06                         278,440,387.76
           利息收入
           已赚保费
           手续费及佣金收入
    二、营业总成本                   155,144,347.99                         118,018,874.60
                                                         华兰生物工程股份有限公司 2015 年第一季度报告全文
       其中:营业成本                                 106,479,792.40                        76,494,294.82
             利息支出
             手续费及佣金支出
             退保金
             赔付支出净额
             提取保险合同准备金净额
             保单红利支出
             分保费用
             营业税金及附加                             1,553,782.06                         2,361,847.75
             销售费用                                   4,978,728.40                         5,865,175.68
             管理费用                                  48,039,452.83                        40,348,125.24
             财务费用                                  -5,907,407.70                        -7,050,568.89
             资产减值损失
       加:公允价值变动收益(损失以“-”号填列)
           投资收益(损失以“-”号填列)              29,862,024.55                        13,072,468.31
           其中:对联营企业和合营企业的投资收益        -2,267,792.27                          -273,071.35
           汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)                    172,787,784.62                       173,493,981.47
       加:营业外收入                                   3,201,496.00                        34,882,136.34
           其中:非流动资产处置利得
       减:营业外支出                                    705,655.43                             83,222.37
           其中:非流动资产处置损失                      108,548.24                              8,321.50
    四、利润总额(亏损总额以“-”号填列)                175,283,625.19                       208,292,895.44
       减:所得税费用                                  29,743,408.66                        34,988,038.67
    五、净利润(净亏损以“-”号填列)                    145,540,216.53                       173,304,856.77
       归属于母公司所有者的净利润                     149,576,847.82                       174,398,390.97
       少数股东损益                                    -4,036,631.29                        -1,093,534.20六、其他综合收益的税后净额
    归属母公司所有者的其他综合收益的税后净额
       (一)以后不能重分类进损益的其他综合收益
             1.重新计量设定受益计划净负债或净资产的变动
             2.权益法下在被投资单位不能重分类进损益的其他综合收益中享有的份额
       (二)以后将重分类进损益的其他综合收益
                                                                   华兰生物工程股份有限公司 2015 年第一季度报告全文
             1.权益法下在被投资单位以后将重分类进损益的其他综合收益中享有的份额
             2.可供出售金融资产公允价值变动损益
             3.持有至到期投资重分类为可供出售金融资产损益
             4.现金流量套期损益的有效部分
             5.外币财务报表折算差额
             6.其他
    归属于少数股东的其他综合收益的税后净额
    七、综合收益总额                                                145,540,216.53                         173,304,856.77
       归属于母公司所有者的综合收益总额                         149,576,847.82                         174,398,390.97
       归属于少数股东的综合收益总额                              -4,036,631.29                          -1,093,534.20八、每股收益:
       (一)基本每股收益                                               0.2573                                0.3002
       (二)稀释每股收益                                               0.2573                                0.3002本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元,上期被合并方实现的净利润为:0.00 元。
    法定代表人:安康                          主管会计工作负责人:谢军民                       会计机构负责人:王建体4、母公司利润表
                                                                                                             单位:元
                 项目                              本期发生额                             上期发生额
    一、营业收入                                                    213,298,625.43                         190,051,057.50
       减:营业成本                                              77,326,085.84                          67,956,603.30
           营业税金及附加                                          999,055.14                            1,602,733.89
           销售费用                                               3,842,204.81                           1,530,045.03
           管理费用                                              20,775,064.16                          12,202,401.92
           财务费用                                              -5,176,852.68                          -8,818,929.88
           资产减值损失
       加:公允价值变动收益(损失以“-”号填列)
           投资收益(损失以“-”号填
                                                                 28,285,111.84                           6,680,524.54列)
           其中:对联营企业和合营企
                                                                 -2,267,792.27                            -273,071.35业的投资收益
    二、营业利润(亏损以“-”号填列)                              143,818,180.00                         122,258,727.78
                                         华兰生物工程股份有限公司 2015 年第一季度报告全文
       加:营业外收入                   1,000,000.00                        34,045,299.33
           其中:非流动资产处置利得
       减:营业外支出                    514,096.64                              7,902.50
           其中:非流动资产处置损失         6,815.71                             7,902.50三、利润总额(亏损总额以“-”号填
                                      144,304,083.36                       156,296,124.61列)
       减:所得税费用                  21,645,612.51                        23,485,379.40
    四、净利润(净亏损以“-”号填列)    122,658,470.85                       132,810,745.21五、其他综合收益的税后净额
       (一)以后不能重分类进损益的其他综合收益
             1.重新计量设定受益计划净负债或净资产的变动
             2.权益法下在被投资单位不能重分类进损益的其他综合收益中享有的份额
       (二)以后将重分类进损益的其他综合收益
             1.权益法下在被投资单位以后将重分类进损益的其他综合收益中享有的份额
             2.可供出售金融资产公允价值变动损益
             3.持有至到期投资重分类为可供出售金融资产损益
             4.现金流量套期损益的有效部分
             5.外币财务报表折算差额
             6.其他
    六、综合收益总额                      122,658,470.85                       132,810,745.21七、每股收益:
       (一)基本每股收益
       (二)稀释每股收益5、合并现金流量表
                                                                                 单位:元
                                                      华兰生物工程股份有限公司 2015 年第一季度报告全文
                   项目                  本期发生额                       上期金额发生额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                291,238,166.32                          294,745,904.59
    客户存款和同业存放款项净增加额
    向中央银行借款净增加额
    向其他金融机构拆入资金净增加额
    收到原保险合同保费取得的现金
    收到再保险业务现金净额
    保户储金及投资款净增加额
    处置以公允价值计量且其变动计入当期损益的金融资产净增加额
    收取利息、手续费及佣金的现金
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还
    收到其他与经营活动有关的现金                 20,339,526.76                             47,265,539.91
    经营活动现金流入小计                            311,577,693.08                          342,011,444.50
    购买商品、接受劳务支付的现金                162,657,185.71                          134,744,581.86
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
    支付利息、手续费及佣金的现金
    支付保单红利的现金
    支付给职工以及为职工支付的现金               39,049,318.56                             33,431,430.79
    支付的各项税费                               42,144,349.15                             45,775,322.45
    支付其他与经营活动有关的现金                 31,595,043.41                             24,070,542.43
    经营活动现金流出小计                            275,445,896.83                          238,021,877.53
    经营活动产生的现金流量净额                       36,131,796.25                          103,989,566.97二、投资活动产生的现金流量:
    收回投资收到的现金                          960,000,000.00                          342,000,000.00
    取得投资收益收到的现金                       32,129,816.82                             13,345,539.66
    处置固定资产、无形资产和其他长期资
                                                       4,790.00产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
                                                          华兰生物工程股份有限公司 2015 年第一季度报告全文
       收到其他与投资活动有关的现金
    投资活动现金流入小计                                992,134,606.82                           355,345,539.66
       购建固定资产、无形资产和其他长期资
                                                     35,339,381.66                            18,036,677.79产支付的现金
       投资支付的现金                               805,000,000.00                           627,000,000.00
       质押贷款净增加额
       取得子公司及其他营业单位支付的现金净额
       支付其他与投资活动有关的现金
    投资活动现金流出小计                                840,339,381.66                           645,036,677.79
    投资活动产生的现金流量净额                          151,795,225.16                           -289,691,138.13三、筹资活动产生的现金流量:
       吸收投资收到的现金
       其中:子公司吸收少数股东投资收到的现金
       取得借款收到的现金
       发行债券收到的现金
       收到其他与筹资活动有关的现金筹资活动现金流入小计
       偿还债务支付的现金                                                                     90,000,000.00
       分配股利、利润或偿付利息支付的现金                                                       1,245,000.00
       其中:子公司支付给少数股东的股利、利润
       支付其他与筹资活动有关的现金
    筹资活动现金流出小计                                                                          91,245,000.00
    筹资活动产生的现金流量净额                                                                    -91,245,000.00
    四、汇率变动对现金及现金等价物的影响                     -292,462.06                              33,461.51
    五、现金及现金等价物净增加额                        187,634,559.35                           -276,913,109.65
       加:期初现金及现金等价物余额                 671,421,714.21                        1,027,260,672.95
    六、期末现金及现金等价物余额                        859,056,273.56                           750,347,563.306、母公司现金流量表
                                                                                                    单位:元
                   项目                     本期发生额                          上期发生额一、经营活动产生的现金流量:
                                           华兰生物工程股份有限公司 2015 年第一季度报告全文
    销售商品、提供劳务收到的现金       200,178,274.62                        172,435,232.85
    收到的税费返还
    收到其他与经营活动有关的现金        79,284,497.95                         48,878,931.46
    经营活动现金流入小计                   279,462,772.57                        221,314,164.31
    购买商品、接受劳务支付的现金       114,069,812.10                         84,652,084.70
    支付给职工以及为职工支付的现金      11,970,163.57                          9,324,770.72
    支付的各项税费                      27,010,220.73                         26,559,058.93
    支付其他与经营活动有关的现金        11,962,075.14                          9,886,822.21
    经营活动现金流出小计                   165,012,271.54                        130,422,736.56
    经营活动产生的现金流量净额             114,450,501.03                         90,891,427.75二、投资活动产生的现金流量:
    收回投资收到的现金                 800,000,000.00                        150,000,000.00
    取得投资收益收到的现金              30,552,904.11                          6,953,595.89
    处置固定资产、无形资产和其他长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
    投资活动现金流入小计                   830,552,904.11                        156,953,595.89
    购建固定资产、无形资产和其他长期
                                        18,816,313.82                         11,472,108.39资产支付的现金
    投资支付的现金                     655,000,000.00                        500,000,000.00
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
    投资活动现金流出小计                   673,816,313.82                        511,472,108.39
    投资活动产生的现金流量净额             156,736,590.29                       -354,518,512.50三、筹资活动产生的现金流量:
    吸收投资收到的现金
    取得借款收到的现金
    发行债券收到的现金
    收到其他与筹资活动有关的现金筹资活动现金流入小计
    偿还债务支付的现金
    分配股利、利润或偿付利息支付的现
                                           华兰生物工程股份有限公司 2015 年第一季度报告全文金
    支付其他与筹资活动有关的现金筹资活动现金流出小计筹资活动产生的现金流量净额
    四、汇率变动对现金及现金等价物的影响      -292,462.06                                   33,461.51
    五、现金及现金等价物净增加额           270,894,629.26                              -263,593,623.24
    加:期初现金及现金等价物余额      297,461,012.90                              682,699,844.20
    六、期末现金及现金等价物余额           568,355,642.16                              419,106,220.96二、审计报告第一季度报告是否经过审计□ 是 √ 否公司第一季度报告未经审计。
                                                        华兰生物工程股份有限公司
                                                               董事长:安康
                                                              2015 年 4 月 23 日
数据加载中...
prevnext
手机查看股票